1
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Kane RC, Bross PF, Farrell AT and Pazdur
R: Velcade: U.S. FDA approval for the treatment of multiple myeloma
progressing on prior therapy. Oncologist. 8:508–513. 2003.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Iyer L and Ratain MJ: Pharmacogenetics and
cancer chemotherapy. Eur J Cancer. 34:1493–1499. 1998. View Article : Google Scholar : PubMed/NCBI
|
4
|
Vangsted A, Klausen TW and Vogel U:
Genetic variations in multiple myeloma II: association with effect
of treatment. Eur J Haemotol. 88:93–117. 2012. View Article : Google Scholar
|
5
|
Uttamsingh V, Lu C, Miwa G and Gan LS:
Relative contributions of the five major human cytochromes P450,
1A2, 2C9, 2C19, 2D6 and 3A4, to the hepaticmetabolism of the
proteasome inhibitor bortezomib. Drug Metab Dispos. 33:1723–1728.
2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Timm R, Kaiser R, Lötsch J, et al:
Association of cyclophosphamide pharmacokinetics to polymorphic
cytochrome P450 2C19. Pharmacogenomics J. 5:365–373. 2005.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Li Y, Hou J, Jiang H, et al: Polymorphisms
of CYP2C19 gene are associated with the efficacy of thalidomide
based regimens in multiple myeloma. Haematologica. 92:1246–1249.
2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Vangsted AJ, Søeby K, Klausen TW, et al:
No influence of the polymorphisms CYP2C19 and CYP2D6 on the
efficacy of cyclophosphamide, thalidomide and bortezomib in
patients with multiple myeloma. BMC Cancer. 10:4042010. View Article : Google Scholar : PubMed/NCBI
|
9
|
Anderson KC, Bensinger W, Alsina M, et al:
Multiple myeloma. In: NCCN Clinical Practice Guidelines in Oncology
(NCCN Guidelines®). Version 1. 2013, http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed.
March 12–2014
|
10
|
Durie BG, Harousseau JL, Miguel JS, et al
International Myeloma Working Group: International uniform response
criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006.
View Article : Google Scholar : PubMed/NCBI
|
11
|
The Human Cytochrome P450 (CYP) Allele
Nomenclature Database. http://www.cypalleles.ki.se/Accessed. 20–Mar.
2014
|
12
|
Dai D, Tang J, Rose R, Hodgson E,
Bienstock RJ, Mohrenweiser HW and Goldstein JA: Identification of
variants of CYP3A4 and characterization of their abilities to
metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther.
299:825–831. 2001.PubMed/NCBI
|
13
|
Kang YS, Park SY, Yim CH, et al: The
CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid
metabolizer of sex steroids, is associated with low bone mineral
density. Clin Pharmacol Ther. 85:312–318. 2009. View Article : Google Scholar : PubMed/NCBI
|
14
|
Lamba JK, Lin YS, Schuetz EG and Thummel
KE: Genetic contribution to variable human CYP3A-mediated
metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
|
15
|
Vangsted AJ, Klausen TW, Ruminski W, et
al: The polymorphism IL-1beta T-31C is associated with a longer
overall survival in patients with multiple myeloma undergoing
auto-SCT. Bone Marrow Transplant. 43:539–545. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Vangsted A, Gimsing P, Klausen TW, et al:
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence
treatment outcome in multiple myeloma patients undergoing
autologous bone marrow transplantation. Int J Cancer.
120:1036–1045. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Vangsted AJ, Klausen TW, Gimsing P,
Andersen NF, Abildgaard N, Gregersen H and Vogel U: A polymorphism
in NFKB1 is associated with improved effect of interferon-{alpha}
maintenance treatment of patients with multiple myeloma after
high-dose treatment with stem cell support. Haematologica.
94:1274–1281. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Badros A, Goloubeva O, Dalal JS, et al:
Neurotoxicity of bortezomib therapy in multiple myeloma: a
single-center experience and review of the literature. Cancer.
110:1042–1049. 2007. View Article : Google Scholar : PubMed/NCBI
|